About Axsome Therapeutics, Inc.
https://www.axsome.comAxsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.
CEO
Herriot Tabuteau
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 150
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Needham
Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
UBS
Buy
B of A Securities
Buy
Truist Securities
Buy
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:4.18M
Value:$740.02M
BLACKROCK, INC.
Shares:3.79M
Value:$671.03M
BLACKROCK INC.
Shares:3.3M
Value:$584.13M
Summary
Showing Top 3 of 414
About Axsome Therapeutics, Inc.
https://www.axsome.comAxsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $170.99M ▲ | $205.19M ▲ | $-47.23M ▲ | -27.62% ▲ | $-0.94 ▲ | $-44.38M ▼ |
| Q2-2025 | $150.04M ▲ | $173.31M ▲ | $-47.97M ▲ | -31.97% ▲ | $-0.97 ▲ | $-42.57M ▲ |
| Q1-2025 | $121.46M ▲ | $168.66M ▼ | $-59.41M ▲ | -48.91% ▲ | $-1.22 ▲ | $-54.85M ▲ |
| Q4-2024 | $118.77M ▲ | $180.87M ▲ | $-74.91M ▼ | -63.08% ▼ | $-1.54 ▼ | $-70.54M ▼ |
| Q3-2024 | $104.76M | $158.95M | $-64.6M | -61.67% | $-1.34 | $-60.56M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $325.27M ▲ | $669.25M ▲ | $595.52M ▲ | $73.73M ▲ |
| Q2-2025 | $303.02M ▲ | $639.78M ▲ | $566.71M ▲ | $73.08M ▲ |
| Q1-2025 | $300.91M ▼ | $596.67M ▲ | $543.47M ▲ | $53.2M ▼ |
| Q4-2024 | $315.35M ▼ | $568.5M ▲ | $511.48M ▲ | $57.02M ▼ |
| Q3-2024 | $327.34M | $561.46M | $468.56M | $92.9M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-47.23M ▲ | $1.05M ▲ | $-58K ▼ | $21.27M ▼ | $22.26M ▲ | $988K ▲ |
| Q2-2025 | $-47.97M ▲ | $-32.42M ▲ | $-13K ▲ | $34.54M ▲ | $2.11M ▲ | $-32.42M ▲ |
| Q1-2025 | $-59.41M ▲ | $-43.38M ▼ | $-338K ▼ | $29.27M ▲ | $-14.44M ▼ | $-43.38M ▼ |
| Q4-2024 | $-74.91M ▼ | $-26.2M ▼ | $-30K ▲ | $14.24M ▼ | $-11.99M ▼ | $-26.23M ▼ |
| Q3-2024 | $-64.6M | $-18.63M | $-90K | $30.41M | $11.68M | $-18.48M |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 Product | $200.00M ▲ | $150.00M ▼ | $120.00M ▼ | $170.00M ▲ |
 Royalty | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q3-2025 | Q2-2025 |
|---|---|---|---|---|
 NonUS | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $120.00M ▲ | $120.00M ▲ | $170.00M ▲ | $150.00M ▼ |
CEO
Herriot Tabuteau
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 150
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Needham
Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
UBS
Buy
B of A Securities
Buy
Truist Securities
Buy
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:4.18M
Value:$740.02M
BLACKROCK, INC.
Shares:3.79M
Value:$671.03M
BLACKROCK INC.
Shares:3.3M
Value:$584.13M
Summary
Showing Top 3 of 414